Publikationen
Unsere Forschungsergebnisse erscheinen in internationalen Publikationen in Peer-Reviewed Journals, außerdem in Kongressbeiträgen, Vorträgen und Postern und wissenschaftlichen Fachveranstaltungen.
Übersicht über unsere Publikationen
STAT5B leukemic mutations, altering SH2 tyrosine 665, have opposing impacts on immune gene programs. Life Sci Alliance
Lee HK, Chen J, Philips RL, Lee SG, Feng X, Wu Z, Liu C, Schultz AB, Dalzell M, Meggendorfer M, Haferlach C, Birnbaum F, Sexton JA, Keating AE, O'Shea JJ, Young NS, Villarino AV, Furth PA, Hennighausen L. STAT5B leukemic mutations, altering SH2 tyrosine 665, have opposing impacts on immune gene programs. Life Sci Alliance. 2025.
Mehr erfahrenAcute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report
Wobst J, Truger M, Baer C, Meggendorfer M, Kern W, Haferlach T, Haferlach C. Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report. Haematologica. 2025.
Mehr erfahrenEnhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q
Sollier E, Riedel A, Toprak UH, Wierzbinska JA, Weichenhan D, Schmid JP, Hakobyan M, Touzart A, Jahn E, Vick B, Brown-Burke F, Kelly K, Kelekci S, Pejkovska A, Goyal A, Bähr M, Breuer K, Chen MM, Llamazares-Prada M, Hartmann M, Schönung M, Correia N, Trumpp A, Abdullah Y, Klingmüller U, Mughal SS, Brors B, Westermann F, Ulrich E, Autry RJ, Schlesner M, Vosberg S, Herold T, Greif PA, Pfeifer D, Lübbert M, Fischer T, Heidel FH, Gebhard G, Walter W, Haferlach T, Eisfeld AK, Mrózek K, Nicolet D, Bullinger L, Smeenk L, Erpelinck-Verschueren C, Mulet-Lazaro R, Delwel R, Ernst A, Scherer M, Lutsik P, Jeremias I, Döhner K, Döhner H, Lipka DB, Plass C.. Enhancer hijacking discovery in acute myeloid leukemia by pyjacker identifies MNX1 activation via deletion 7q. Blood Cancer Discov. 2025.
Mehr erfahrenHaematolymphoid malignancies: beyond the current classifications
de Jong D, Haferlach T. Haematolymphoid malignancies: beyond the current classifications. Histopathology. 2025.
Mehr erfahrenMyeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity.
Summerer I, Walter W, Meggendorfer M, Haferlach T, Dicker F, Hutter S, Nadarajah N, Stengel A, Kuehn C, Kern W, Bennett JM, Haferlach C, Pohlkamp C.. Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity. Blood Cancer Journal. 2025.
Mehr erfahrenClinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT.
Gurnari C, Robin M, Adès L, Aljurf M, Almeida AM, Barroso Duarte F, Bernard E, Cutler CS, Della Porta MG, de Witte TM, DeZern AE, Drozd-Sokolowska J, Duncavage EJ, Fenaux P, Gagelmann N, Garcia-Manero G, Haferlach C, Haferlach T, Hasserjian RP, Hellstrom-Lindberg ES, Jacoby MA, Kulasekararaj AG, Coleman Lindsley R, Maciejewski JP, Makishima H, Malcovati L, Mittelman M, Myhre AE, Ogawa S, Onida F, Papaemmanuil E, Passweg JR, Platzbecker U, Pleyer L, Raj K, Santini V, Sureda A, Tobiasson M, Voso MT, Yakoub-Agha I, Zeidan AM, Walter MJ, Kröger N, McLornan DP, Cazzola M. Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT. Blood. 2025.
Mehr erfahrenVAE-Surv: A novel approach for genetic-based clustering and prognosis prediction in myelodysplastic syndromes.
Rollo C, Pancotti C, Sartori F, Caranzano I, D'Amico S, Carota L, Casadei F, Birolo G, Lanino L, Sauta E, Asti G, Buizza A, Delleani M, Zazzetti E, Bicchieri M, Maggioni G, Fenaux P, Platzbecker U, Diez-Campelo M, Haferlach T, Castellani G, Della Porta MG, Fariselli P, Sanavia T. VAE-Surv: A novel approach for genetic-based clustering and prognosis prediction in myelodysplastic syndromes. Comput Methods Programs Biomed. 2025.
Mehr erfahren